Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Olof G Karlsson

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Ebiomedicine|August 31, 2019
Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?Jan Olof G Karlsson
European Thyroid Journal|October 25, 2025
Rationale behind the European Thyroid Association 2024 Guideline to treat the Allan-Herndon-Dudley syndrome with tiratricol?Jan Olof G Karlsson
Journal of Hepatology|April 20, 2004
Antioxidant activity of mangafodipir is not a new findingJan Olof G Karlsson
Biochemical Pharmacology|May 12, 2024
Comments on "Clinically relevant therapeutic approaches against acetaminophen (APAP) hepatotoxicity and acute liver failure"Jan Olof G Karlsson, Per Jynge
Acta Oncologica (Stockholm, Sweden)|December 16, 2017
Is it possible to draw firm conclusions from the PLIANT trial?Jan Olof G Karlsson, Per Jynge
Journal of Pharmacological Sciences|March 22, 2025
Letter to the editorJan Olof G Karlsson, Per Jynge
International Journal of Molecular Sciences|April 27, 2024
Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca<sub>4</sub>Mn(DPDP)<sub>5</sub>, MnDPDP and DPDPJan Olof G Karlsson, Per Jynge
British Journal of Pharmacology|January 11, 2003
Acetylcholine-induced vasodilation may depend entirely upon NO in the femoral artery of young pigletsRagnhild Støen, Kristin Lossius, Jan Olof G Karlsson
Antioxidants (Basel, Switzerland)|September 3, 2020
Comment on "Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity" <i>Antioxidants</i> 2020, <i>9</i>, 594Jan Eric Stehr, Ingemar Lundström, Jan Olof G Karlsson
Antioxidants (Basel, Switzerland)|December 24, 2021
The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOxJan Olof G Karlsson, Per Jynge, Louis J Ignarro
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Ebiomedicine|August 31, 2019
Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?Jan Olof G Karlsson
European Thyroid Journal|October 25, 2025
Rationale behind the European Thyroid Association 2024 Guideline to treat the Allan-Herndon-Dudley syndrome with tiratricol?Jan Olof G Karlsson
Journal of Hepatology|April 20, 2004
Antioxidant activity of mangafodipir is not a new findingJan Olof G Karlsson
Biochemical Pharmacology|May 12, 2024
Comments on "Clinically relevant therapeutic approaches against acetaminophen (APAP) hepatotoxicity and acute liver failure"Jan Olof G Karlsson, Per Jynge
Acta Oncologica (Stockholm, Sweden)|December 16, 2017
Is it possible to draw firm conclusions from the PLIANT trial?Jan Olof G Karlsson, Per Jynge
Journal of Pharmacological Sciences|March 22, 2025
Letter to the editorJan Olof G Karlsson, Per Jynge
International Journal of Molecular Sciences|April 27, 2024
Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca<sub>4</sub>Mn(DPDP)<sub>5</sub>, MnDPDP and DPDPJan Olof G Karlsson, Per Jynge
British Journal of Pharmacology|January 11, 2003
Acetylcholine-induced vasodilation may depend entirely upon NO in the femoral artery of young pigletsRagnhild Støen, Kristin Lossius, Jan Olof G Karlsson
Antioxidants (Basel, Switzerland)|September 3, 2020
Comment on "Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity" <i>Antioxidants</i> 2020, <i>9</i>, 594Jan Eric Stehr, Ingemar Lundström, Jan Olof G Karlsson
Antioxidants (Basel, Switzerland)|December 24, 2021
The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOxJan Olof G Karlsson, Per Jynge, Louis J Ignarro
Pageof 3